Therefore, lipid-lowering and NPY down-regulation pharmacological interventions might reduce the risk of hyperlipidemia-induced serum hormonal complications such as testosterone decline, hyperinsulinemia, and increased cortisol levels. This evidence concerns the gene NPY and Hyperinsulinemia.